There is a significant variation in quality of urgent healthcare provided during virtual visits, according to a new study published in JAMA Internal Medicine.
There is a significant variation in quality of urgent healthcare provided during virtual visits, according to a new study published in JAMA Internal Medicine. Especially for management of common acute illnesses, the variation stood true in the performance and not in the mode of communication.
Commercial virtual visits are an increasingly popular model of healthcare for the management of common acute illnesses. These virtual visits enable patients access a website to be connected synchronously—via videoconference, telephone, or webchat—to a physician with whom they have no prior relationship. So this has no in-person care option. Such virtual visits are becoming increasingly popular as they guarantee easy and timely access to care.
A very common complaint from patients is that when they really need urgent attention, they rarely get appointments on the same or next day. Having a virtual care option eliminates the time factor and enables urgent care by physicians.
The researchers conducted this study to better understand the variation in the quality of urgent healthcare among virtual visit companies.
Study Method and Results
For research purposes, only 6 common acute illnesses were considered: ankle pain, streptococcal pharyngitis, viral pharyngitis, acute rhinosinusitis, low back pain, and recurrent female urinary tract infection. Data was collected from May 2013 to July 2014 from 67 trained standardized patients accessing 8 commercial virtual visit websites with the highest web traffic. All encounters were either through telephone or videoconferencing.
The final analysis was based on the completeness of histories and physical examinations, the correct diagnosis (vs an incorrect or no diagnosis), and adherence to guidelines of key management decisions.
The authors found:
Virtual Settings Need Improvement
It was found that the antibiotic prescription rates varied hugely in an online virtual setting compared with a traditional visit setting. The prescription rates were lower in a virtual setting. Antibiotic prescription is definitely an area that needs attention.
Another area that needs improvement is the rates of testing. In virtual settings, physicians didn't suggest patient to seek additional testings, which may not be a bad thing altogether, but needs to be looked into because sometimes appropriate use of testing is critical to the delivery of medical care and identification, the authors noted.
Commercial virtual visit companies are becoming hugely popular with a user base of almost 6 million people.
“The urgency of the need to develop a regulatory framework or industry-promulgated standards will depend, in part, on how much quality of care varies among virtual visit companies,” the researchers concluded.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Polatuzumab Vedotin and R-CHP Appropriate for Untreated DLBCL
April 24th 2024Population pharmacokinetic and exposure-response analyses revealed a favorable benefit-risk profilane for the treatment combination of polatuzumab vedotin and rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP).
Read More